Revealed: women GPs shut out from corridors of power
GPs can use strontium ranelate for primary and secondary prevention of osteoporosis, but
only as a second-line treatment, NICE has provisionally ruled.
Women with appropriate risk factors and T-scores can receive the drug if bisphosphonates are contraindicated or patients have not responded to them, the institute's draft update on secondary prevention recommends.
New draft guidance on primary prevention also suggests second-line use in the relevant age groups, according to T-score and risk factors.But Dr Pam Brown, vice-chair of the primary care forum of the National Osteoporosis Society and a GP in Swansea, said: ‘It is not clear why strontium ranelate has been relegated to use only as an alternative to bisphosphonates.'